RE:RE:RE:RE:NASDAQ listing rulesSecuring a definitive agreement with a prominent pharmaceutical partner could propel the company past the market cap threshold for Nasdaq, just on signing, & facilitating capital from institutional investors. A potential Nasdaq listing as an optimal milestone, it will elevate the company off the pathetic Venture and open the company to plus hundred million more investors. The question remains: Barium, iodine, fullerene, or a blend? Only time can answer, yet any collaboration with a major pharmaceutical entity promises an instantaneous and substantial reassessment of the company's value. An increased market capitalization with a Big Pharma partner will open the flood gates from institutional investments into Voyageur. This prospective partnership stands as a pivotal catalyst for potentially elevating the share price from mere cents to substantial dollar figures.